Jean-baptiste B. Bachet

Jean-baptiste B. Bachet

Villejuif, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 165 publications

Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study.

Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 03, 2026

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026

Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study.

Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study.

Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026

Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol.

Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol.

Journal: BMJ open
Published: June 30, 2026

Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.

Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.

Journal: Journal of the National Cancer Institute
Published: April 14, 2026

€2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France.

€2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France.

Journal: Clinics and research in hepatology and gastroenterology
Published: February 03, 2026

Prognostic and Predictive Values of Transcriptomic Signatures in Metastatic Pancreatic Cancer: A Biomarker Analysis of Three French Multicenter Prospective Randomized Controlled Phase 2 Trials (Prodige35, Prodige37 and AFUGEM).

Prognostic and Predictive Values of Transcriptomic Signatures in Metastatic Pancreatic Cancer: A Biomarker Analysis of Three French Multicenter Prospective Randomized Controlled Phase 2 Trials (Prodige35, Prodige37 and AFUGEM).

Journal: Cancer letters
Published: January 23, 2026

Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France).

Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France).

Journal: EClinicalMedicine
Published: January 07, 2026

Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.

Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.

Journal: Nature
Published: October 20, 2025

Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.

Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.

Journal: International journal of molecular sciences
Published: October 10, 2025

Reply to: Random Assignment, But Without Comparison: A Missed Opportunity.

Reply to: Random Assignment, But Without Comparison: A Missed Opportunity.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 11, 2025

PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.

PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 16, 2025
Showing 1-12 of 165

Last Updated: 09/26/2026